---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055654"
form_type: "8-K"
ticker: null
cik: "0001496323"
company_name: "IGM Biosciences, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:44:08.471357+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Q1 net loss narrows to $49.8M; aplitabart colorectal trial enrollment exceeds target

## Summary
- Net loss $49.8M ($0.83/share) vs $59.3M ($1.33/share) in Q1 2023; operating expenses decreased.
- Cash and investments $293.8M at March 31, 2024, down from $337.7M at Dec 31, 2023.
- Aplitabart randomized colorectal trial enrollment exceeded target of 110 patients, now over 120; top-line PFS data expected by Q1 2025.
- Imvotamab completed first dose cohort in rheumatoid arthritis (6 active, 2 placebo); two higher-dose cohorts planned.
- FY 2024 guidance: GAAP OpEx $210-220M; collaboration rev ~$63M (mostly Q2); cash runway into Q2 2026.

## SEC filing metadata
- accession: 0000950170-24-055654
- form_type: 8-K
- cik: 0001496323
- company_name: IGM Biosciences, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1496323/000095017024055654/0000950170-24-055654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1496323/000095017024055654/igms-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055654
- JSON: https://secwatch.observer/filing/0000950170-24-055654.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055654.txt

## Key facts
- Earnings Releases
  IGM Biosciences, Inc. reported the fiscal quarter ended March 31, 2024 results: net income $49.8 million, or a loss of $0.83 per share, EPS $0.83 per share.
  - Period: the fiscal quarter ended March 31, 2024
  - Net income: $49.8 million, or a loss of $0.83 per share
  - EPS: $0.83 per share
  - Result: reported results
  source text: For the first quarter of 2024, net loss was $49.8 million, or a loss of $0.83 per share, compared to a net loss of $59.3 million, or a loss of $1.33 per share, for the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1496323/000095017024055654/0000950170-24-055654-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.